Modeling the potential effect of cabamiquine-pyronaridine for chemoprevention against Plasmodium falciparum malaria
Antimicrobial Agents and Chemotherapy · 04.11.2026 · 70 (11)
DOI: 10.1128/aac.00434-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.11.2026. Verfasst von Lucy C Okell und 6 weiteren Autor:innen. Beteiligte Einrichtung: MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom. Hauptthemen laut MEDLINE: Malaria, Falciparum, Antimalarials, Plasmodium falciparum, Naphthyridines. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Global Health R&D of Merck Healthcare, Ares Trading S.A. (an affiliate of Merck KGaA, Darmstadt, Germany), Community Jameel.
Abstract (Originalsprache)
Preventive treatment (chemoprevention) is a key intervention for reducing the burden of Plasmodium falciparum malaria in children. The impact of the current widely used drug combination, sulfadoxine-pyrimethamine-amodiaquine (SP-AQ), is challenged by emerging drug resistance and adherence to multi-day dosing. Cabamiquine is a novel antimalarial with activity against liver- and blood-stage malaria parasites, administered as a single dose, and under development in combination with pyronaridine. We used mathematical modeling to translate early phase 1 clinical results into estimates of its potential impact as malaria chemoprevention. Pharmacokinetic-pharmacodynamic (PKPD) models of cabamiquine and pyronaridine were combined, assuming Bliss independence, to estimate time-varying protection against infection. PKPD results were incorporated into an established individual-based malaria transmission model to estimate the impact of seasonal malaria chemoprevention (SMC) across settings with differing transmission and seasonality. Cabamiquine-pyronaridine was predicted to provide protection of >95% for approximately 4 weeks, slightly outperforming SP-AQ even in children who fully adhere to SP-AQ treatment. Six weeks after treatment, cabamiquine-pyronaridine protection dropped for the regimens containing
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom.
- Merck Institute for Pharmacometrics, Ares Trading S.A. (an affiliate of Merck KGaA, Darmstadt, Germany), Lausanne, Switzerland.
- The Healthcare Business of Merck KGaA, Darmstadt, Germany.
- Global Health R&D of Merck Healthcare, Ares Trading S.A. (an affiliate of Merck KGaA, Darmstadt, Germany), Eysins, Switzerland.
ORCID-Profile: Lucy C Okell, Perrine Courlet, Claudia Demarta, Thomas Spangenberg
Förderung
- Medical Research Council
- Global Health R&D of Merck Healthcare, Ares Trading S.A. (an affiliate of Merck KGaA, Darmstadt, Germany)
- Community Jameel
Zitieren
APA
Okell, L. C., Courlet, P., Venezia, F., Oeuvray, C., Demarta, C., Spangenberg, T., & Okebe, J. (2026). Modeling the potential effect of cabamiquine-pyronaridine for chemoprevention against Plasmodium falciparum malaria. Antimicrobial Agents and Chemotherapy, 70(11). https://doi.org/10.1128/aac.00434-26
Vancouver
Okell LC, Courlet P, Venezia F, Oeuvray C, Demarta C, Spangenberg T, et al. Modeling the potential effect of cabamiquine-pyronaridine for chemoprevention against Plasmodium falciparum malaria. Antimicrobial Agents and Chemotherapy. 2026;70(11). doi:10.1128/aac.00434-26
BibTeX
@article{Okell2026,
author = {Okell, Lucy C and Courlet, Perrine and Venezia, Filippo and Oeuvray, Claude and Demarta, Claudia and Spangenberg, Thomas and Okebe, Joseph},
title = {Modeling the potential effect of cabamiquine-pyronaridine for chemoprevention against Plasmodium falciparum malaria},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {11},
doi = {10.1128/aac.00434-26}
}
EUVIMED